Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?

Shares of Corcept Therapeutics (CORT) have gained 11.8% over the past four weeks to close the last trading session at $47.27, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$67.60 indicates a potential upside of 43%. The average comprises five short-term price targets ranging from a low of $45 to a high of$78, with a standard deviation of $13.32. While the lowest estimate indi ...